Array ( [0] => Applebot/0.1 [1] => facebookexternalhit/1.1 [2] => LinkedInBot/1.0 [3] => meta-externalagent/1.1 [4] => Amazonbot/0.1 [5] => BLEXBot/1.0 [6] => DotBot/1.2 [7] => Qwantbot/1.0_1997801 [8] => AhrefsBot/7.0 [9] => DataForSeoBot/1.0 [10] => MatchorySearch/1.3 [11] => WRTNBot/1.0 [12] => Sogou web spider/4.0 [13] => MojeekBot/0.11 [14] => Yeti/1.1 [15] => SeznamBot/4.0 [16] => SemrushBot-SI/0.97 [17] => MistralAI-User/1.0 [18] => Qwantbot/1.0 [19] => coccocbot-web/1.0 [20] => coccocbot-image/1.0 [21] => PlagAwareBot/3.2 [22] => Barkrowler/0.9 [23] => AwarioSmartBot/1.0 [24] => PetalBot [25] => archive.org_bot [26] => Iframely/1.3.1 [27] => LogRocket-AssetCacher [28] => Slackbot 1.0 [29] => node-fetch/1.0 [30] => MJ12bot/v1.4.8 [31] => MJ12bot/v2.0.0 [32] => Timpibot/0.9 [33] => AwarioBot/1.0 [34] => MJ12bot/v2.0.1 [35] => Qwantbot/1.0_2850318 [36] => SiteAuditBot/0.97 [37] => Scrapy/2.11.2 [38] => CCBot/2.0 [39] => MJ12bot/v2.0.2 [40] => Scrapy/2.13.3 [41] => WordPress/6.8.3 [42] => MJ12bot/v2.0.4 [43] => SemrushBot/7~bl [44] => Qwairy-Bot/1.0 [45] => Embedly/0.2 [46] => GeedoProductSearch [47] => SemrushBot [48] => vkShare [49] => inkrich [50] => Discordbot/2.0 [51] => IbouBot/1.0 [52] => trafilatura/1.6.3 [53] => AnsehnBot/1.0 [54] => WP-URLDetails/6.8.3 [55] => HubSpot Crawler [56] => ShapBot/0.1.0 [57] => udu/1.6.5 [58] => aiohttp/3.13.1 [59] => l9scan/2.0 [60] => Trident/5.0 [61] => SmartBotCrawler/1.0 [62] => ) The user agent is not in the allowed list.Array ( [0] => pingbot/2.0 [1] => Googlebot/2.1 [2] => ChatGPT-User/1.0 [3] => PerplexityBot/1.0 [4] => OAI-SearchBot/1.0 [5] => GPTBot/1.2 [6] => Perplexity-User/1.0 [7] => YandexBot/3.0 [8] => YandexFavicons/1.0 [9] => AdsBot-Google-Mobile [10] => AdsBot-Google [11] => Gemini-Deep-Research [12] => DuckAssistBot/1.1 [13] => DuckDuckBot/1.1 [14] => GoogleOther [15] => YandexRenderResourcesBot/1.0 [16] => YandexImages/3.0 [17] => DuckAssistBot/1.2 [18] => Baiduspider/2.0 [19] => Baiduspider-render/2.0 [20] => bingbot/2.0 [21] => YandexUserproxy [22] => Pingdom.com_bot_version_1.4_ [23] => GPTBot/1.3 [24] => PingdomPageSpeed/1.0 [25] => YandexMobileBot/3.0 [26] => OAI-SearchBot/1.3 [27] => ClaudeBot/1.0 [28] => OAI-SearchBot/1.3 [29] => ) The user agent is an allowed/known agent.
Aortic Aneurysm Market Size & Growth Forecast 2026–2035, By Segments (Type, Treatment, Product, End-use), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Base Year Value (2025)
USD 6.11 Billion
CAGR (2026-2035)
10.5%
Forecast Year Value (2035)
USD 16.58 Billion
Historical Data Period
2022-2025
Largest Region
North America
Forecast Period
2026-2035
Aortic Aneurysm Market Intelligence Snapshot:
-
Regional Market Dynamics:
- North America accounted for 48.76% of the market in 2025, supported by established vascular care pathways, advanced diagnostic imaging, strong hospital infrastructure, and high procedural adoption for aneurysm management.
- Asia Pacific is projected to grow at an 11.76% CAGR as expanding hospital capabilities, improved vascular diagnosis, minimally invasive procedures, and broader access to specialist care accelerate treatment adoption.
-
Segment Momentum:
- Abdominal Aortic Aneurysm (AAA) held a 61.38% share in 2025 due to established screening pathways, consistent diagnosis, and well-defined treatment practices that support steady clinical management and intervention volumes.
- EVAR is the fastest-growing treatment and held a 57.47% share in 2025 because clinicians increasingly prefer minimally invasive procedures that improve treatment accessibility and fit modern vascular care pathways.
-
Market Expansion Drivers:
- Increasing prevalence of aortic aneurysms driven by aging population and cardiovascular risk factors.
- Growth of minimally invasive EVAR and TEVAR procedures improving patient outcomes.
- Expansion of national screening programs enabling early aneurysm detection and treatment.
-
Leading Market Participants:
Prominent players in the aortic aneurysm market include Medtronic plc (Ireland), W. L. Gore & Associates, Inc. (United States), Cook Medical LLC (United States), Boston Scientific Corporation (United States), Endologix LLC (United States), MicroPort Scientific Corporation (China), Artivion, Inc. (United States), Lombard Medical Technologies GmbH (Germany), Braile Biomédica S.A. (Brazil), Cordis Corporation (United States).
Global Market Forecast Snapshot:
-
Market Outlook:
- 2025 Market Size: USD 6.11 Billion
- 2026 Market Size: USD 15.2 billion
- Projected Market Size: USD 16.58 Billion by 2035
- Growth Forecasts: 10.5% CAGR (2026-2035)
-
Regional and Segment Outlook:
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Abdominal Aortic Aneurysm (AAA) (Type) | Endovascular Aneurysm Repair (EVAR) (Treatment) | Stent Grafts (Product) | Hospitals (End-use)
- Emerging Opportunity Segment: Thoracic Aortic Aneurysm (TAA) (Type) | Endovascular Aneurysm Repair (EVAR) (Treatment) | Catheters (Product) | Ambulatory Surgery Centers (End-use)
Market Growth Drivers and Industry Trends
Increasing prevalence of aortic aneurysms driven by aging population and cardiovascular risk factorsRising exposure to age-related vascular degeneration, hypertension, smoking history, and atherosclerotic disease is steadily enlarging the addressable patient pool for the aortic aneurysm market. As more patients present with incidental findings during cardiovascular imaging or enter surveillance after diagnosis, hospitals and vascular specialists are managing a larger volume of monitoring, risk stratification, and intervention decisions. This trends purchasing and treatment activity toward aneurysm repair devices, follow-up imaging, and specialist care pathways, reinforcing market demand through both newly diagnosed cases and the ongoing management needs of patients who are not treated immediately.
Growth of minimally invasive EVAR and TEVAR procedures improving patient outcomes
The wider adoption of endovascular aneurysm repair (EVAR) and thoracic endovascular aortic repair (TEVAR) is reshaping treatment patterns in the aortic aneurysm market by making intervention feasible for patients who may not be ideal candidates for open surgery. Shorter hospital stays, lower perioperative burden, and faster recovery are influencing physician preference and hospital protocol, which supports stronger use of stent graft systems, delivery catheters, and related imaging-guided procedural tools. As centers build endovascular capabilities and referral networks increasingly direct patients toward less invasive options, procedure volumes rise through practical gains in treatment accessibility and clinician confidence.
Expansion of national screening programs enabling early aneurysm detection and treatment
Broader implementation of organized screening is increasing the number of aneurysms identified before rupture or acute presentation, which changes how demand develops in the aortic aneurysm market. Earlier detection moves more patients into structured surveillance and elective treatment pathways, where clinicians can plan interventions under more controlled conditions and select devices based on anatomical suitability rather than emergency constraints. This improves the flow of diagnosed patients into vascular care services and supports market expansion by converting previously undetected disease into measurable demand for imaging, monitoring, and scheduled repair procedures.
| Growth Driver Assessment Framework | |||||
| Growth Driver | Impact On CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Increasing prevalence of aortic aneurysms driven by aging population and cardiovascular risk factors | 2.40% | High | North America, Europe | High | Near Term |
| Growth of minimally invasive EVAR and TEVAR procedures improving patient outcomes | 2.10% | High | North America, Europe, Asia Pacific | High | Mid Term |
| Expansion of national screening programs enabling early aneurysm detection and treatment | 1.80% | High | Europe, North America | Medium | Long Term |
Unlock insights tailored to your business with our bespoke market research solutions - Click to get your customized report now!
Regional Demand Dynamics
Largest Region
North America
48.76% Market Share in 2025
North America held the leading regional share of the aortic aneurysm market in 2025, accounting for 48.76% share, backed by established vascular care pathways, broad access to advanced diagnostic imaging, and high procedural adoption across major treatment centers. The region’s leadership is reinforced by routine detection through well-developed screening and referral systems, which brings more patients into specialist care earlier and supports steady demand for both surveillance and intervention. Strong hospital infrastructure and familiarity with endovascular and surgical repair techniques also help sustain procedure volumes in everyday clinical practice.
Asia Pacific is projected to expand at an 11.76% CAGR over the forecast period, with growth in the aortic aneurysm market being fueled by improving access to vascular diagnosis and treatment across developing healthcare systems. Expansion of hospital capabilities, rising availability of minimally invasive procedures, and broader patient access to specialist services are accelerating adoption in practice. As more healthcare providers build capacity to identify and manage aneurysm cases, the region is seeing stronger procedural momentum and a wider treatment base across key markets.
| Regional Market Attractiveness & Strategic Fit Matrix | |||||
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub | Advanced | Developing | Advanced | Developing | Developing |
| Cost-Sensitive Region | Low | High | Medium | High | High |
| Regulatory Environment | Supportive | Neutral | Supportive | Neutral | Neutral |
| Demand Drivers | Strong | Strong | Strong | Moderate | Moderate |
| Development Stage | Developed | Developing | Developed | Developing | Emerging |
| Adoption Rate | High | High | High | Medium | Medium |
| New Entrants / Startups | Moderate | Moderate | Moderate | Sparse | Sparse |
| Macro Indicators | Strong | Strong | Stable | Stable | Stable |
Key Country Insights
The U.S. aortic aneurysm market is shaped by widespread use of endovascular repair technologies and increasing emphasis on surveillance programs for high-risk patients. Hospitals in the U.S. continue investing in minimally invasive devices and imaging-guided interventions to improve procedural outcomes.
Japan's aortic aneurysm market is influenced by a large elderly population requiring long-term monitoring and intervention. Healthcare providers in Japan increasingly favor minimally invasive repair approaches and routine imaging surveillance to reduce complications associated with aneurysm progression.
South Korea is integrating advanced imaging and catheter-based procedures into aortic aneurysm treatment strategies. The market in South Korea benefits from strong tertiary care infrastructure and growing use of sophisticated endovascular devices in major cardiovascular centers.
Germany prioritizes evidence-based vascular treatment pathways and specialized cardiovascular centers for aortic aneurysm management. Demand in Germany is supported by the adoption of advanced stent graft systems and continued focus on improving treatment efficiency for aging patient populations.
France emphasizes coordinated screening and referral pathways to identify aneurysm cases earlier and optimize treatment planning. French healthcare institutions continue to adopt less invasive repair techniques while strengthening multidisciplinary vascular care services.
Italy's aortic aneurysm market relies on established vascular surgery centers that manage complex aneurysm cases and support device adoption. In Italy, clinicians are increasingly balancing conventional surgery with endovascular procedures to improve patient recovery and resource utilization.
Segment Leadership and Growth Trends
Abdominal Aortic Aneurysm (AAA) held the dominant position in the aortic aneurysm market in 2025, accounting for a 61.38% share. its position is underpinned by the higher procedural and diagnostic focus placed on abdominal aneurysms in routine vascular care, where established screening pathways and clearer intervention thresholds support steady case identification and treatment volumes. This keeps Abdominal Aortic Aneurysm (AAA) firmly dominant in the aortic aneurysm market, as it remains the segment most consistently addressed across standard clinical practice.
Thoracic Aortic Aneurysm (TAA) is the fastest-growing segment in the aortic aneurysm market as clinical attention increasingly shifts toward earlier detection and management of more complex aortic conditions. Growth is being backed by improving diagnostic reach and rising treatment readiness for thoracic cases, which historically faced greater procedural complexity than abdominal aneurysms. As care capabilities strengthen, Thoracic Aortic Aneurysm (TAA) is gaining momentum faster than alternatives because a larger share of previously under-addressed patients is now moving into active monitoring and intervention pathways.
Treatment Segment Analysis: Endovascular Aneurysm Repair (EVAR) (Largest & Fastest-Growing Segment)
In 2025, Endovascular Aneurysm Repair (EVAR) led the aortic aneurysm market with a 57.47% share, while also recording the fastest growth within the treatment segment. Its strong position reflects the market’s clear preference for less invasive aneurysm management approaches that fit more efficiently into current vascular treatment pathways and support broader procedural adoption. The continued expansion of Endovascular Aneurysm Repair (EVAR) in the aortic aneurysm market is being reinforced by its practical alignment with evolving clinical practice, where treatment decisions increasingly favor interventions that can improve procedural accessibility and patient throughput without relying on open surgical management.
| Report Segmentation | |||
| Segment | Sub-Segment | Largest Segment | Fastest Growing Segment |
|---|---|---|---|
| Type | Thoracic Aortic Aneurysm (TAA), Abdominal Aortic Aneurysm (AAA) | Abdominal Aortic Aneurysm (AAA) | Thoracic Aortic Aneurysm (TAA) |
| Treatment | Open Surgical Repair (OSR), Endovascular Aneurysm Repair (EVAR) | Endovascular Aneurysm Repair (EVAR) | Endovascular Aneurysm Repair (EVAR) |
| Product | Stent Grafts, Catheters | Stent Grafts | Catheters |
| End-use | Hospitals, Ambulatory Surgery Centers, Clinics | Hospitals | Ambulatory Surgery Centers |
Read our Research ApproachCompetitive Landscape and Market Positioning
Company Profile
Business Overview Financial Highlights Product Landscape SWOT Analysis Recent Developments Company Heat Map Analysis
1. Medtronic plc (Ireland)
2. W. L. Gore & Associates Inc. (United States)
3. Cook Medical LLC (United States)
4. Boston Scientific Corporation (United States)
5. Endologix LLC (United States)
6. MicroPort Scientific Corporation (China)
7. Artivion Inc. (United States)
8. Lombard Medical Technologies GmbH (Germany)
9. Braile Biomédica S.A. (Brazil)
10. Cordis Corporation (United States)
In the aortic aneurysm market, innovation is focused on improving diagnostic precision and treatment effectiveness. Collaborative clinical research initiatives are supporting the development of advanced therapeutic approaches. New solution introductions are enhancing procedural outcomes, while continuous technological improvements are strengthening patient care standards in the aortic aneurysm market.
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Nectero | Apr-26 | Nectero, supported by Boston Scientific, reported positive mid-stage clinical results for its EAST System (PGG therapy), showing slowed abdominal aortic aneurysm growth in 90% of patients over two years. The ongoing Phase II/III trial is critical for validating the device’s disease-modifying potential in managing AAA, representing a significant shift toward pharmaceutical-like intervention in vascular surgery. |
| W. L. Gore & Associates | Jul-25 | W. L. Gore & Associates secured CE Mark approval for its lower-profile GORE VIABAHN VBX Balloon Expandable Endoprosthesis. Compatibility with 6 Fr sheaths enhances the device's utility as a bridging stent for complex FEVAR and BEVAR procedures, supporting improved procedural efficiency and technical flexibility in endovascular aneurysm repair. |
| Vivasure Medical | Jun-25 | Vivasure Medical received approval for its PerQseal Elite, a fully bioresorbable, sutureless vascular closure device. The system allows for streamlined large-bore closure in interventions including EVAR, potentially reducing complications and enhancing procedural safety during minimally invasive cardiovascular surgeries across European markets. |
| Endoron Medical | Jul-24 | Endoron Medical secured $10 million in Series A funding led by Sofinnova Partners to accelerate the clinical validation of its Aortoseal catheter-based endostapling system. The capital supports early feasibility studies and development aimed at improving fixation technology in endovascular abdominal aortic aneurysm repair, addressing critical durability requirements for complex aortic procedures. |
| Shape Memory Medical | Mar-24 | Shape Memory Medical closed a $38 million Series C financing round to scale its proprietary shape memory polymer-based embolic technology. The investment supports the commercial expansion of its endovascular embolisation portfolio, targeting improved clinical outcomes for vascular conditions, including complex aortic aneurysms, by leveraging advanced material science in minimally invasive repair. |
| Terumo Aortic | Jul-24 | Terumo Aortic successfully completed the first commercial implantation of its Fenestrated TREO device in Asia. This milestone marks a significant geographic expansion for the company’s advanced endovascular aneurysm repair (EVAR) portfolio, strengthening its competitive positioning in high-growth regional markets requiring sophisticated solutions for complex aortic anatomies. |
| Bentley | Nov-24 | Bentley announced the first-in-human implantation of its BeFlared bridging stent graft system. This clinical milestone validates the device's design, which aims to improve aortic aneurysm repair by offering enhanced graft support and deployment precision, directly addressing technical challenges associated with treating complex vascular anatomies. |
Frequently Asked Questions
How much is the aortic aneurysm market worth?
The market valuation of the aortic aneurysm is USD 6.68 billion in 2026.
How is the aortic aneurysm industry expected to grow over the next 10 years?
Aortic Aneurysm Market size is estimated to increase from USD 6.11 billion in 2025 to USD 16.58 billion by 2035 supported by a CAGR exceeding 10.5% during 2026-2035.
How are aging-related risk factors and expanding screening practices shaping demand in the aortic aneurysm market?
Rising prevalence linked to aging and cardiovascular risk factors is increasing detection of aneurysm cases through routine imaging and screening. This is expanding surveillance requirements, specialist consultations, and structured treatment pathways across vascular care settings.
How is the shift toward minimally invasive EVAR and TEVAR procedures influencing treatment adoption patterns?
EVAR and TEVAR adoption is increasing as less invasive alternatives to open surgery, improving patient eligibility and recovery outcomes. Their use is expanding procedural volumes and supporting broader clinical acceptance across vascular treatment centers.
Why does Abdominal Aortic Aneurysm (AAA) dominate the aortic aneurysm market?
Abdominal Aortic Aneurysm (AAA) held a 61.38% share in 2025 due to established screening pathways, consistent diagnosis, and well-defined treatment practices that support steady clinical management and intervention volumes.
Why is Endovascular Aneurysm Repair (EVAR) the fastest-growing treatment in the aortic aneurysm market?
EVAR is the fastest-growing treatment and held a 57.47% share in 2025 because clinicians increasingly prefer minimally invasive procedures that improve treatment accessibility and fit modern vascular care pathways.
Why does North America lead the aortic aneurysm market?
North America accounted for 48.76% of the market in 2025, supported by established vascular care pathways, advanced diagnostic imaging, strong hospital infrastructure, and high procedural adoption for aneurysm management.
Why is Asia Pacific the fastest-growing region in the aortic aneurysm market?
Asia Pacific is projected to grow at an 11.76% CAGR as expanding hospital capabilities, improved vascular diagnosis, minimally invasive procedures, and broader access to specialist care accelerate treatment adoption.
What are the key competitors in the aortic aneurysm landscape?
Prominent players in the aortic aneurysm market include Medtronic plc (Ireland), W. L. Gore & Associates, Inc. (United States), Cook Medical LLC (United States), Boston Scientific Corporation (United States), Endologix LLC (United States), MicroPort Scientific Corporation (China), Artivion, Inc. (United States), Lombard Medical Technologies GmbH (Germany), Braile Biomédica S.A. (Brazil), Cordis Corporation (United States).
Our Clients
Why Choose Us
Specialized Expertise: Our team comprises industry experts with a deep understanding of your market segment. We bring specialized knowledge and experience that ensures our research and consulting services are tailored to your unique needs.
Customized Solutions: We understand that every client is different. That's why we offer customized research and consulting solutions designed specifically to address your challenges and capitalize on opportunities within your industry.
Proven Results: With a track record of successful projects and satisfied clients, we have demonstrated our ability to deliver tangible results. Our case studies and testimonials speak to our effectiveness in helping clients achieve their goals.
Cutting-Edge Methodologies: We leverage the latest methodologies and technologies to gather insights and drive informed decision-making. Our innovative approach ensures that you stay ahead of the curve and gain a competitive edge in your market.
Client-Centric Approach: Your satisfaction is our top priority. We prioritize open communication, responsiveness, and transparency to ensure that we not only meet but exceed your expectations at every stage of the engagement.
Continuous Innovation: We are committed to continuous improvement and staying at the forefront of our industry. Through ongoing learning, professional development, and investment in new technologies, we ensure that our services are always evolving to meet your evolving needs.
Value for Money: Our competitive pricing and flexible engagement models ensure that you get maximum value for your investment. We are committed to delivering high-quality results that help you achieve a strong return on your investment.
Select Licence Type
